Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07038876 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by MapLight Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07038876: Recruiting Phase 2 study of Schizophrenia, sponsored by MapLight Therapeutics.
NCT07038876 is a Phase 2 study of Schizophrenia that is actively recruiting participants, run by MapLight Therapeutics. The registered enrollment target is 300 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07038876, a Phase 2 study of Schizophrenia, is actively recruiting participants, sponsored by MapLight Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.
Primary Outcome
The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ML-007C-MA BID
- DRUG ML-007C-MA QD
Study Locations (20)
California
- Clinical Site - Bellflower
- Clinical Site - Culver City
- Clinical Site - Garden Grove
- Clinical Site - Lemon Grove
- Clinical Site - Los Angeles
- Clinical Site - Montclair
- Clinical Site - Orange
- Clinical Site - Riverside
- Clinical Site - San Diego
- Clinical Site - Santee
- Clinical Site - Sherman Oaks
- Clinical Site - Torrance
Florida
- Clinical Site - Hollywood
- Clinical Site - Miami Lakes
- Clinical Site - West Palm Beach
Georgia
- Clinical Site - Atlanta
- Clinical Site - Decatur
Arkansas
- Clinical Site - Little Rock
Illinois
- Clinical Site - Chicago
New Jersey
- Clinical Site - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT07038876 shows while recruiting
NCT07038876 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07038876 names 20 study sites across 6 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07038876 about?
NCT07038876 is a clinical study titled "A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia". ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary ob...
What is the current status of trial NCT07038876?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-06-27. Estimated completion is 2026-08.
What conditions does trial NCT07038876 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07038876?
The interventions under investigation include: Placebo (DRUG), ML-007C-MA BID (DRUG), ML-007C-MA QD (DRUG).
Who is sponsoring clinical trial NCT07038876?
This trial is sponsored by MapLight Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07038876 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07038876's enrollment target sits among peer trials
300 57th of 315 higher than 255 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
-
A Study of ANAVEX3-71 in Adults With Schizophrenia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI